Yaron Naos - Aug 15, 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role: Sr. VP, Operations
Signature: /s/ Eyal Rubin, POA
Stock symbol: PLX
Transactions as of: Aug 15, 2023
Transactions value $: $0
Form type: 4
Date filed: 8/17/2023, 04:30 PM
Previous filing: Sep 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLX	Common Stock	Award		+187K	+1390.51%		201K	Aug 15, 2023	By Trust	F1, F2
holding	PLX	Common Stock						7.11K	Aug 15, 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
F2	To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

Content

Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.